ACRX AcelRx Pharmaceuticals Inc.

1.73
-0.02  -1%
Previous Close 1.75
Open 1.72
Price To Book -4.81
Market Cap 137,661,292
Shares 79,573,001
Volume 542,758
Short Ratio
Av. Daily Volume 1,031,024
Stock charts supplied by TradingView

NewsSee all news

  1. AcelRx Announces Year-End 2019 Metrics and Provides Corporate Updates

    REDWOOD CITY, Calif., Jan. 13, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for

  2. AcelRx Pharmaceuticals Announces Publication Analyzing Pooled Dosing and Efficacy Data on Sufentanil Sublingual 30 mcg Tablets

    REDWOOD CITY, Calif., Nov. 13, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in

  3. AcelRx Pharmaceuticals Reports Third Quarter 2019 Financial Results

    REDWOOD CITY, Calif., Nov. 6, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use

  4. AcelRx Pharmaceuticals to Present at Credit Suisse 28th Annual Healthcare Conference

    REDWOOD CITY, Calif., Nov. 5, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in

  5. AcelRx to announce third quarter 2019 results and provide an update on the company's business on Wednesday, November 6th, 2019

    REDWOOD CITY, Calif., Oct. 28, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company, today announced that it will release third quarter financial results after market close

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data released August 15 2016
ARX-04 (SAP302)
Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury
FDA Approval announced November 2, 2018.
DSUVIA (ARX-04)
Moderate-to-severe acute pain following a surgical procedure
CRL Jul 26 2014. NDA resubmission timing to be known in 2H 2019.
Zalviso
Post-operative pain following open abdominal surgery and hip or knee replacement surgery

Latest News

  1. AcelRx Announces Year-End 2019 Metrics and Provides Corporate Updates

    REDWOOD CITY, Calif., Jan. 13, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for

  2. AcelRx Pharmaceuticals Announces Publication Analyzing Pooled Dosing and Efficacy Data on Sufentanil Sublingual 30 mcg Tablets

    REDWOOD CITY, Calif., Nov. 13, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in

  3. AcelRx Pharmaceuticals Reports Third Quarter 2019 Financial Results

    REDWOOD CITY, Calif., Nov. 6, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use

  4. AcelRx Pharmaceuticals to Present at Credit Suisse 28th Annual Healthcare Conference

    REDWOOD CITY, Calif., Nov. 5, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in

  5. AcelRx to announce third quarter 2019 results and provide an update on the company's business on Wednesday, November 6th, 2019

    REDWOOD CITY, Calif., Oct. 28, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company, today announced that it will release third quarter financial results after market close